ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Antiviral drugs >Dideoxyinosine

Dideoxyinosine

Dideoxyinosine Suppliers list
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-66670886
Email: info@dakenchem.com
Products Intro: Product Name:Dideoxyinosine
CAS:69655-05-6
Purity:99.00% Package:100g,500g,1KG,10KG,100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:69655-05-6
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: career henan chemical co
Tel: +86-371-86658258
Email: sales@coreychem.com
Products Intro: Product Name:Dideoxyinosine
CAS:69655-05-6
Purity:99% Package:5KG;5USD
Company Name: Hebei Guanlang Biotechnology Co., Ltd.
Tel:
Email: sales3@crovellbio.com
Products Intro: Product Name:Dideoxyinosine
CAS:69655-05-6
Purity:99% Package:1PCS;10USD
Company Name: Nanjing Baifuli Technology Co., Ltd.
Tel: +86-15335185688
Email: sales@unisyn.cn
Products Intro: Product Name:Didanosine
CAS:69655-05-6
Purity:98% Package:On Request

Lastest Price from Dideoxyinosine manufacturers

  • Dideoxyinosine
  • US $15.00-10.00 / KG
  • 2021-07-13
  • CAS:69655-05-6
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
  • Dideoxyinosine
  • US $15.00-10.00 / KG
  • 2021-07-09
  • CAS:69655-05-6
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
Dideoxyinosine Basic information
Product Name:Dideoxyinosine
Synonyms:bmy40900;ddino;nsc612049;2',3'-Dideoxy inosine(DDI);DDI, Didanosine;2.3-Dideoxy;2',3'-Dideoxy-D-inosine;DIDANOSINE / 2'',3''-DIDEOXYINOSINE
CAS:69655-05-6
MF:C10H12N4O3
MW:236.23
EINECS:614-994-4
Product Categories:Inhibitors;API's;Nucleosides, Nucleotides & Related Reagents;Bases & Related Reagents;Intermediates & Fine Chemicals;Videx, Videx EC;Heterocyclic Compounds;Antivirals for Research and Experimental Use;Biochemistry;Chemical Reagents for Pharmacology Research;Nucleosides and their analogs;Nucleotides;Pharmaceuticals
Mol File:69655-05-6.mol
Dideoxyinosine Structure
Dideoxyinosine Chemical Properties
Melting point 193-195 °C
Boiling point 193-195 C
alpha D25 -26.3° (c = 10 in water)
density 1.2917 (rough estimate)
refractive index -28 ° (C=0.34, H2O)
storage temp. Inert atmosphere,Store in freezer, under -20°C
solubility Soluble in DMSO or methanol
form Powder
pka9.12(at 25℃)
color White to Off-white
Water Solubility 1-5 g/100 mL at 21 ºC
Merck 14,3098
BRN 3619529
Stability:Stable. Combustible. Incompatible with strong oxidizing agents.
CAS DataBase Reference69655-05-6(CAS DataBase Reference)
IARC3 (Vol. 76) 2000
EPA Substance Registry SystemInosine, 2',3'-dideoxy- (69655-05-6)
Safety Information
Hazard Codes C
Risk Statements 34-36/37
Safety Statements 26-27-36/37/39-45-24/25
WGK Germany 2
RTECS NM7460700
HS Code 29335990
Hazardous Substances Data69655-05-6(Hazardous Substances Data)
MSDS Information
ProviderLanguage
Dideoxyinosine English
SigmaAldrich English
Dideoxyinosine Usage And Synthesis
DescriptionDidanosine is an orally active purine dideoxynucleoside analog indicated for adult and pediatric patients with advanced HIV infection who are either intolerant or significantly deteriorated on zidovudine. It appears to increase CD4 cell counts and decrease p24 antigen levels.Major adverse effects are pancreatitis, peripheral neuropathy and diarrhea.Unlike zidovudine, didanosine exhibits insignificant bone marrow suppression.
Chemical PropertiesWhite Powder
OriginatorNational Cancer Institute(NIH) (U.S.A.)
UsesUsed as an antiviral
UsesAntiviral;Transrcriptase inverse inhibitor
DefinitionChEBI: A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen.
IndicationsDidanosine (ddI, Videx) is an adenosine analogue with activity against HIV-1, HIV-2, and HTLV-I. It is approved as part of a multidrug regimen for the therapy of HIV infection and is also used as postexposure HIV prophylaxis
Manufacturing ProcessIn a 500 ml flask with a shoulder was separately charged 50 ml of medium (pH 7.0) containing 0.5 g/dl of yeast extract, 1.0 g/dl of peptone, 1.0 g/dl of meat extract and 0.5 g/dl of NaCl followed by sterilization. One platinum loop of each microorganism shown in Table which had been preincubated in bouillon agar medium at 30°C for 16 hours was inoculated on the medium followed by shake culture at 30°C for 16 hours. After the cells were isolated from the obtained culture solution by centrifugal separation, the cells were washed with 0.05 M Tris-HCl buffer (pH 7.2) and further centrifuged to give washed cells.
The washed cells described above were added to 0.05 M Tris-HCl buffer (pH 7.2) containing 1 g/dl of 2',3'-dideoxyadenosine in a concentration of 5 g/dl followed by reacting at 30°C for 2 hours. The amount of 2',3'-dideoxyinosine produced at this stage is shown in the next Table.
This way 2',3'-dideoxyinosine may be produced from 2',3'-dideoxyadenosine in a short period of time, by contacting microorganisms supplied at low cost, products containing the same or treated products thereof, with a substrate.
Brand nameVidex (Bristol-Myers Squibb).
Therapeutic FunctionAntiviral
Antimicrobial activityDidanosine is active against HIV-1, HIV-2 and HTLV-1.
Acquired resistanceCodon changes at positions 65 or 74 in HIV reverse transcriptase are associated with reduced susceptibility.
General DescriptionFluffy white solid or powder. Condenses at 347°F and darkens at approximately 572°F. Odorless.
General DescriptionDidanosine (Videx, ddI) is 2',3'-dideoxyinosine (ddI), a synthetic purine nucleoside analog that is bioactivatedto 2',3'-dideoxy-ATP (ddATP) by host cellularenzymes.The metabolite, ddATP, accumulates intracellularly,where it inhibits RT and is incorporated intoviral DNA to cause chain termination in HIVinfectedcells. The potency of didanosine is 10-to 100-foldless than that of AZT with respect to antiviral activity andcytotoxicity, but the drug causes less myelosuppressionthan AZT causes.
Didanosine is recommended for the treatment of patientswith advanced HIV infection who have received prolongedtreatment with AZT but have become intolerant to, or experiencedimmunosuppression from, the drug. AZT and ddIact synergistically to inhibit HIV replication in vitro, andddI is effective against some AZT-resistant strains of HIV.Painful peripheral neuropathy (tingling, numbness, and painin the hands and feet) and pancreatitis (nausea, abdominalpain, elevated amylase) are the major dose-limiting toxicitiesof didanosine. Didanosine is given orally in the form ofbuffered chewable tablets or as a solution prepared from thepowder. Both oral dosage forms are buffered to preventacidic decomposition of ddI to hypoxanthine in the stomach.
Air & Water ReactionsWater soluble.
Health HazardSYMPTOMS: Symptoms of exposure to a related compound include cutaneous eruptions, fever, mouth sores, thrombocytopenia, neutropenia, reversible peripheral neuropathy, gastrointestinal distress, headache, nausea and vomiting.
Fire HazardFlash point data for Dideoxyinosine are not available; however, Dideoxyinosine is probably combustible.
Pharmaceutical ApplicationsAn analog of deoxyadenosine, formulated for oral administration.
Mechanism of actionDidanosine (ddl) is a purine dideoxynucleoside, which is an analogue of inosine. Chemically, it is 2′,3′-dideoxyinosine, and it differs from inosine by having hydrogen atoms in place of the 2′- and 3′-hydroxyl groups on the ribose ring. Didanosine is a pro-drug that is bioactivated by metabolism to dideoxyadenosine triphosphate, which is a competitive inhibitor of viral RT and is incorporated into the developing viral DNA in place of deoxyladenosine triphosphate. As such, this agent causes chain termination because of the absence of a 3′-hydroxyl group. Didanosine inhibits HIV RT and exerts a virustatic effect on the retroviruses. Combined with ZDV, antiretroviral activity of ddI is increased.
PharmacokineticsOral absorption: c. 40%
Cmax 400 mg once daily: 0.93 mg/L
Plasma half-life: c. 1.4 h
Volume of distribution: c. 1 L/kg
Plasma protein binding: <5%
Absorption
Bioavailability is reduced by about half when taken with food and the drug should be given at least 30 min before a meal. The peak plasma concentration achieved by enteric-coated tablets is less than half that of buffered tablets.
Distribution
Central nervous system (CNS) penetration is relatively poor. Median concentrations in semen (455 ng/mL; range < 50–2190 ng/mL) are greater than those in blood (<50 ng/mL; range <50–860 ng/mL). It is secreted in breast milk.
Metabolism
Based upon animal studies it is presumed that metabolism occurs by the pathways responsible for the elimination of endogenous purines by xanthine oxidase. Metabolism may be altered in patients with severe hepatic impairment; however, no specific dose adjustment is recommended.
Excretion
Renal clearance by glomerular filtration and active tubular secretion accounts for 50% of total body clearance. Urinary recovery accounts for about 20% of the oral dose in adults. The half-life increases three-fold in patients requiring dialysis. Patients with a creatinine clearance <60 mL/min may be at greater risk of toxicity.
Clinical UseTreatment of HIV infection (in combination with other antiretroviral drugs)
Clinical UseThe most common adverse effect produced by didanosine is diarrhea.Abdominal pain, nausea, vomiting, anorexia, and dose-related peripheral neuropathy may occur. Pancreatitis occurs rarely, as do hyperuricemia, bone marrow suppression, retinal depigmentation, and optical neuritis. Resistance to didanosine appears to result from mutations different from those responsible for zidovudine resistance.
Side effectsMost serious are pancreatitis (fatal and non-fatal), lactic acidosis and severe hepatomegaly with steatosis (fatal and nonfatal), retinopathy, optic neuritis and dose-related peripheral neuropathy. Patients with low body weight may require dose modification. A strong association with non-cirrhotic portal hypertension has been described.
The combination with stavudine should be avoided in pregnant women as fatal cases of lactic acidosis have been reported. Caution should also be exercised in patients with known risk factors for liver disease. Therapy should be stopped in patients who develop clinical or laboratory evidence of lactic acidosis or hepatotoxicity. Monitoring lactate levels prospectively is not recommended as mild hyperlactatemia occurs in asymptomatic patients and has a poor positive predictive value for the development of lactic acidosis.
Caution should be exercised in co-administering other drugs with known neurotoxicity and in patients with a history of neuropathy. Treatment should stop if symptoms and signs of neuropathy are observed, but the condition is usually reversible and patients with resolved neuropathy may be retreated at a reduced dosage. Retinal depigmentation has been observed in children and twice-yearly dilated retinal examination is recommended.
MetabolismDidanosine is less toxic than ZDV. The CSF fluid/plasma ratio of ddI is 0.2. Didanosine is ultimately converted to hypoxanthine, xanthine, and uric acid through the usual metabolic pathway for purines. The latter is a nontoxic metabolic product.
Didanosine is given in advanced HIV infection, ZDV intolerance, or significant clinical/immunologic deterioration.
PrecautionsBuffering agents that are compounded with didanosineto counteract its degradation by gastric acid mayinterfere with the absorption of other drugs that requireacidity (e.g., indinavir, delavirdine, ketoconazole, fluoroquinolones,tetracyclines, dapsone). An enteric-coatedformulation (Videx EC) that dissolves in the basic pH ofthe small intestine is not susceptible to these interactions.Ganciclovir and valganciclovir can increase bloodlevels of didanosine.The use of zalcitabine with didanosineis not recommended because that combination carriesan additive risk of peripheral neuropathy.The combinationof didanosine with stavudine increases the riskof pancreatitis, hepatotoxicity, and peripheral neuropa-thy. Stavudine should not be given with didanosine topregnant women because of the increased risk of metabolicacidosis.
Tag:Dideoxyinosine(69655-05-6) Related Product Information
2',3',5'-TRI-O-ACETYLINOSINE INOSINE-5'-TRIPHOSPHORIC ACID, DISODIUM TIMTEC-BB SBB006472 8-AMINOGUANOSINE GUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT 2'-Deoxyinosine 2-AMINO-8-BROMO-9-((2R,3R,4S,5R)-3,4-DIHYDROXY-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-2-YL)-1,9-DIHYDRO-PURIN-6-ONE 5'-O-Dimethoxytrityl-N-isobutyryl-deoxyguanosine 3'-GMP DISODIUM SALT 2',3'-DIDEOXYGUANOSINE 5'-TRIPHOSPHATE TETRASODIUM SALT N2-ISOBUTYRYL-3'-O-BENZOYL-2'-DEOXYGUANOSINE 5'-O-(4,4'-DIMETHOXYTRITYL)-N2-ISOBUTYRYL-2'-DEOXYGUANOSINE-3'-(METHYL-N,N-DIISOPROPYL)PHOSPHORAMIDITE INOSINE-3',5'-CYCLIC PHOSPHATE N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT 2'-Deoxyguanosine-5'-diphosphate trisodium salt 2',3'-O-Isopropylideneinosine N2-Isobutyryl-2'-deoxyguanosine 8-BR-CGMP